Daily non-political popular news in brief.

Study demonstrated AMITIZA (lubiprostone) showed efficacy

10-23-2006 · EurekAlert!

Results of a secondary analysis of two pivotal studies were presented today at the 71st Annual Meeting of the American College of Gastroenterology (ACG), and showed that 60 percent of patients treated with AMITIZA (TM) (lubiprostone) experienced a spontaneous bowel movement (SBM) within 24 hours of treatment, and 80 percent experienced a SBM within 48 hours of treatment.

Keywords: study, demonstrated, amitiza, lubiprostone, showed, efficacy

« Previous | Next »

Similar news on "Study demonstrated AMITIZA (lubiprostone) showed efficacy":

New study demonstrates that Lubiprostone may improve symptom relief rates in adults with IBS-C
05-21-2007 · EurekAlert!
A new study demonstrated that the active ingredient in AMITIZA (lubiprostone), given 8 mcg twice a day, may improve symptom relief rates in adults with irritable bowel syndrome with constipation (IBS-C). These results were presented as a late-breaker at Digestive Disease Week 2007, the largest annual international meeting of digestive disease specialists.
Similar news · Read more »
Novel small molecule therapy shows benefit for anemic patients via hydration of red blood cells
02-05-2008 · EurekAlert!
Researchers are identifying innovative therapeutics for sickle cell anemia that focus on specific factors in the disease's progression, such as the important role of hydration of the red blood cells. According to a study prepublished online in Blood, the official journal of the American Society of Hematology, a novel small molecule therapy called senicapoc showed efficacy in maintaining hydration of red blood cells and increasing hemoglobin levels in patients with sickle cell anemia.
Similar news · Read more »
AMITIZA (lubiprostone) Phase III constipation trial results
10-23-2006 · EurekAlert!
In recent studies, AMITIZA (tm) (lubiprostone) demonstrated improvements in relief of symptoms associated with irritable bowel syndrome with constipation (IBS-C), such as abdominal bloating and discomfort.
Similar news · Read more »
Long-term treatment with VYVANSE, first prodrug stimulant, demonstrates significant efficacy in ADHD
05-23-2007 · EurekAlert!
Shire plc today announced that VYVANSE effectively controlled ADHD symptoms in children aged 6 to 12 years. In addition, 95 percent of children taking VYVANSE daily for 12 months showed overall improvement, according to phase 3 open-label extension trial results. Further analysis of phase 2 clinical data demonstrated that VYVANSE provided consistent time to maximum concentration of d-amphetamine from patient to patient. Both studies were presented at the annual meeting of the American Psychiatric Association.
Similar news · Read more »
Cell death suppression increases efficacy of M2 vaccines
01-15-2008 · EurekAlert!
Scientists from Cure Lab, Inc. in collaboration with Boston University School of Medicine published new findings indicating that unmodified M2 may have a negative effect on anti-influenza vaccination. The researchers also demonstrated how this detrimental effect of M2 can be eliminated, thereby allowing any future M2-containing vaccine to be both broadly protective as well as safe. This study appears in the Jan. 16 issue of the online journal PLoS ONE.
Similar news · Read more »
The release of new data from the HVTN 502 HIV vaccine study
11-07-2007 · EurekAlert!
The new analyses revealed today from the STEP HIV vaccine clinical trial are both disappointing and puzzling. At this time, the data offer no clear explanations as to why the vaccine showed no measurable efficacy or why among individuals with background immunity to the adenovirus vector, there were more HIV infections in the vaccinees as compared to those in the placebo group. Analyses of the STEP data are continuing, and it will take some time before we fully understand these results.
Similar news · Read more »
Advance in understanding of blood pressure gene could lead to new treatments
02-04-2007 · EurekAlert!
Research by scientists at UCL (University College London) has clearly demonstrated for the first time the structure and function of a gene crucial to the regulation of blood pressure. The discovery could be important in the search for new treatments for illnesses such as heart disease, the UK's biggest killer. In a paper published online today in Nature Medicine, the team, led by Professor Patrick Vallance and Dr James Leiper, UCL Department of Medicine, reveal the role of the human gene dimethylarginine dimethylaminohydrolase (DDAH), showing that loss of DDAH activity disrupts nitric oxide (NO) production. NO is critical in the regulation of blood pressure, nervous system functions and the immune system. The role of DDAH is to break down modified amino acids (Asymmetric dimethylarginine (ADMA) and monomethyl arginine (L-NMMA)) that are produced by the body and have been shown to inhibit NO synthase. These molecules accumulate in various disease states including diabetes, renal failure and pulmonary and systemic hypertension, and their concentration in plasma (the fluid component of blood) is strongly predicative of cardiovascular disease and death. In a healthy human body, the majority of ADMA is eliminated through active metabolism by DDAH. Scientists have hypothesised that if DDAH function is impaired, NO production is reduced, and that this could be an important feature of increased cardiovascular risk. To examine this pathway in more detail, the researchers deleted the DDAH gene in mice. These mice went on to develop hypertension, or high blood pressure. They also designed specific inhibitors (small molecules) which bind to the active site of human DDAH. These small molecule inhibitors also induced hypertension in mice, confirming the importance of DDAH in the regulation of blood pressure. Dr Leiper, UCL Medicine, said: “These genetic and chemical approaches to disrupt DDAH showed remarkably consistent results, and provide compelling evidence that loss of DDAH function increases the concentration of ADMA and thereby disrupts vascular NO signalling. “There has been considerable scientific interest in this pathway and the role of ADMA as a novel risk factor, but so far there's been little evidence to support the idea that it's a cause of disease, rather than just a marker. Genes and their pathways are crucial to our understanding of cardiovascular disease and a better understanding of DDAH-1 could lead to important new treatments. “It could help us to establish if genetic variation predisposes certain people to these diseases, or whether environmental factors exert some of their effects through modulation of DDAH activity. “Our research also shows that this pathway could be harnessed therapeutically to limit production of NO in certain situations where too much nitric oxide is a bad thing; for example, hypotension and septic shock. These are some of the biggest problems in intensive care medicine and there is a huge unmet need for drug treatments.” The study, which was carried out at UCL's Rayne Institute, was funded by grants from the British Heart Foundation, the Wellcome Trust and the Medical Research Council. Professor Jeremy Pearson, Associate Medical Director of the British Heart Foundation, said: "The unexpected finding in the 1980s that a simple gas, nitric oxide (NO), is made by cells in the blood vessel wall and is a powerful control of blood vessel relaxation led to the award of the Nobel Prize in 1998 to its discoverers. "More recently, there has been increasing evidence that impairment of NO production is likely to be an important factor in the development of heart and circulatory disease, but the mechanisms responsible are not fully understood. "This study suggests for the first time that the loss of the activity of the enzyme DDAH-1 leads to reduced NO production and may cause heart and circulatory disease. These findings are likely to be important in the search for new ways to optimise the health of our blood vessels." ### Notes for Editors 1. For more information, please contact Ruth Metcalfe in the UCL Media Relations Office on tel: +44 (0)20 7679 9739, mobile: +44 (0)7990 675 947, out of hours: +44 (0)7917 271 364, e-mail: r.metcalfe@ucl.ac.uk2. 'Disruption of methylarginine metabolism impairs vascular homeostasis' is published in the February issue of the journal Nature Medicine. Advance online publication is embargoed to 18.00 GMT (13.00 US Eastern) Sunday 4 February 2007. Journalists can obtain copies of the paper by contacting the UCL Media Relations Office.3. The study was funded by the British Heart Foundation, the Wellcome Trust and the Medical Research Council. About UCL Founded in 1826, UCL was the first English university established after Oxford and Cambridge, the first to admit students regardless of race, class, religion or gender, and the first to provide systematic teaching of law, architecture and medicine. In the government's most recent Research Assessment Exercise, 59 UCL departments achieved top ratings of 5* and 5, indicating research quality of international excellence. UCL is the fourth-ranked UK university in the 2006 league table of the top 500 world universities produced by the Shanghai Jiao Tong University. UCL alumni include Mahatma Gandhi (Laws 1889, Indian political and spiritual leader); Jonathan Dimbleby (Philosophy 1969, writer and television presenter); Junichiro Koizumi (Economics 1969, Prime Minister of Japan); Lord Woolf (Laws 1954, Lord Chief Justice of England & Wales); Alexander Graham Bell (Phonetics 1860s, inventor of the telephone), and members of the band Coldplay.
Similar news · Read more »
Students who believe intelligence can be developed perform better
02-07-2007 · EurekAlert!
Two studies that followed junior high students have demonstrated that students who believe intelligence can be developed may improve their math achievement. In each study, which each involved two groups of 12-year-olds, one group believed that intelligence could be expanded. This group in both studies showed improvement in math achievement over time. The findings underscore the importance of students' beliefs about their efforts and the need to strengthen motivation and achievement.
Similar news · Read more »
Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
09-18-2007 · EurekAlert!
Provecta demonstrated minimal side effects, significant efficacy and bystander effect on melanoma tumors in stage III patients.
Similar news · Read more »
Efficacy and safety of Aripiprazole as adjunctive therapy in major depressive disorder
05-22-2007 · EurekAlert!
A study presented today at the 160th Annual Meeting of the American Psychiatric Association showed that, in adults with major depressive disorder, adding ABILIFY(R)(aripiprazole) to antidepressant therapy resulted in significant improvement in the primary endpoint, the MADRS Total Score. A reduction in MADRS Total Score represents improvement in depressive symptoms.
Similar news · Read more »